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Abstract
Background:  Peroxisome proliferators are considered rodent carcinogens that are putative
human non-carcinogens based on the presumed absence of direct genetic toxicity in rodent and
human cells and the resistance of human cells to the induction of peroxisomes by peroxisome
proliferators. The highly sensitive lacZ  plasmid-based transgenic mouse mutation assay was
employed to investigate the mutagenicity of several peroxisome proliferators based on several lines
of evidence suggesting that these agents may in fact exert a genotoxic effect.
Methods: Male and female lacZ-plasmid based transgenic mice were treated at 4 months of age
with 6 doses of 2,333 mg di-2-ethylhexyl phthalate (DHEP), 200 mg Wyeth-14,643, or 90 mg
clofibrate per kg of bodyweight, respectively, over a two-week period. Control animals were
treated with the respective vehicles only (35% propyl glycol for DEHP and Wyeth-14,643
treatment controls and sterile water for clofibrate treatment controls).
The mutant frequency in liver, kidney and spleen DNA was determined as the proportion of
retrieved mutant and wild-type lacZ plasmids expressed in Escherichia Coli C host cells employing a
positive selection system for mutant plasmids.
Results: Exposure to DEHP or Wyeth-14,643 significantly increased the mutant frequency in liver,
but not in kidney or spleen, of both female and male mice. Treatment with clofibrate did not lead
to an increased mutant frequency in any of the organs studied.
Conclusion: The results indicate that some peroxisome proliferators display an organ-specific
mutagenicity in lacZ plasmid-based transgenic mice consistent with historical observations of organ-
and compound-specific carcinogenicity.
Background
Peroxisome proliferators are a chemically and structurally
diverse class of chemical compounds that include phtha-
late esters such as di-2-ethylhexyl phthalate (DEHP),
hypolipidemic drugs, analgesics, uricosuric drugs, and
environmental pollutants. Because of the commercial
value of many agents that do induce peroxisome prolifer-
ation, research efforts have focused on the mechanism of
toxicity/carcinogenicity of these chemicals with the goal
of elucidating a species-specific response. This group of
chemicals has been found to induce liver cancer in rats
and mice, most likely due to oxidative stress from
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peroxisome proliferation and/or increased hepatocellular
proliferation [1]. It has often been claimed that humans
are refractory to the adverse effects of peroxisome prolifer-
ators based on data that indicated little peroxisome prolif-
eration in human liver and no induction in cultured
hepatocytes as well as the observation that no increase in
liver cancer was evident in patients treated with hypolipi-
demic fibrate drugs.
It has been purported that there are several strong lines of
evidence supporting the conclusion that peroxisome pro-
liferation-induced rodent liver carcinogenesis is not rele-
vant to humans [2]. Specifically, Galloway et al. [3]
reported that direct genetic toxicity has been eliminated as
a common mechanism of carcinogenic action for peroxi-
some proliferators in general, based on the absence of
chromosome aberrations in human lymphocytes and
CHO cells following exposure to nafenopin or methyl
clofenapate at dose levels up to those that are toxic. More-
over, Roberts et al. [2] argue that the resistance of human
hepatocyes to the induction of peroxisomes by peroxi-
some proliferators [4-6] as well as the resistance of human
hepatocytes to peroxisome proliferator-mediated induc-
tion of replication and suppression of apoptosis [4-6] pre-
clude the possibility that peroxisome proliferators are
relevant to human carcinogenesis. It should be realized,
however, that the classification of carcinogens as either
genotoxic or non-genotoxic is primarily based on the sen-
sitivity and specificity of the experimental procedure(s)
used to assess whether a particular carcinogen induces
DNA addition products (DNA adducts) and/or DNA
mutations. Notwithstanding the sensitive techniques at
our disposal, the (recognized) inherent limitations of any
technique may obfuscate the true genotoxic nature of a
carcinogen.
The development of transgenic rodent mutation models
has provided the means to determine gene mutations
from virtually any tissue in a relatively quick way. A recent
study by Shane et al. [7] indicated that WY-14,643 is
mutagenic in a lacI bacteriophage lambda-based mouse
mutation assay, causing predominantly G -> T and G -> C
transversion mutations. Subsequently, Deutsch et al. [8]
provided evidence for the genotoxic nature of WY-14,643
when it was shown that exposure of human myeloid
leukemia K562 cells to this peroxisome proliferator
caused extensive DNA damage as measured by the Comet
assay.
These findings indicate that peroxisome proliferators may
pose a cancer risk to rodents, and perhaps humans,
through genotoxic mechanisms. To investigate whether
(rodent) peroxisome proliferators should indeed be con-
sidered as genotoxic agents, lacZ  plasmid-based trans-
genic mice were exposed to either clofibrate, DEHP, or
WY-14,643 and mutant frequencies were assayed in vari-
ous organs at 21 days following the last exposure. DEHP
and WY-14,643 were shown to significantly elevate the
mutant frequency in both male and female liver DNA
while clofibrate, at the dose level studied, was apparently
non-mutagenic in male and female liver.
Methods
Animals and exposures
Male and female lacZ-plasmid transgenic mice were
treated at 4 months of age with 6 doses of 2,333 mg
DEHP, 200 mg WY-14,643, or 90 mg clofibrate per kg of
bodyweight, respectively, over a two-week period. Control
animals were treated with the respective vehicles only
(35% propyl glycol for DEHP and WY-14,643 treatment
controls and sterile water for clofibrate treatment con-
trols). Twenty-one days after the last treatment, animals
were sacrificed and organs were flash-frozen in liquid
nitrogen and stored at -80°C until used for DNA
isolation.
DNA isolation
Organs were homogenized in 9 ml lysis buffer (10 mM
Tris-HCl, pH 8.0; 100 mM NaCl; 10 mM EDTA) using a
Brinkmann homogenizer for 10 sec. SDS (Invitrogen,
Carlsbad, CA) and proteinase K (Invitrogen) were added
to final concentrations of 1% and 0.5 mg/ml, respectively.
The mixture was incubated for 16 hours at 45°C. Subse-
quently, the mixture was extracted once with an equal vol-
ume of buffer-saturated phenol/chloroform/isoamyl
alcohol at a ratio of 25/24/1 (Invitrogen). The aqueous
phase was gently mixed with one fourth volume of 8 M
potassium acetate and extracted with an equal volume of
chloroform/isoamyl alcohol (24/1) prior to ethanol pre-
cipitation. Genomic DNA was digested with 40 units Hin-
dIII (New England BioLabs, Beverly, MA) in the presence
of paramagnetic beads (Dynabeads M450 sheep anti-
mouse IgG, Dynal, Lake Success, NY) that were precoated
with a lacZ/lacI fusion protein (Leven, Bogart, GA). Fol-
lowing two wash steps using 250 µl 1X binding buffer,
plasmid DNA was eluted from the beads with isopropyl-
thio-β-galactoside (IPTG). The retrieved plasmids were
circularized with T4 DNA ligase (Invitrogen) and electro-
porated into E. coli C (∆lacZ, galE -) host cells. To deter-
mine the number of transformants, a small aliquot
(0.1%) of the transformed cells was plated in top-agar
containing 5-bromo-4-chloro-3-indolyl-β-D-galactopyra-
noside (X-gal; Gold Biotechnology, St. Louis, MO). The
majority (99.9%) of the transformed cells was plated in
top-agar containing phenyl-β-galactoside (P-gal; Sigma),
allowing growth of only those cells harboring plasmids
with a mutated lacZ  reporter gene. Mutant frequencies
were calculated as the ratio between the number of colo-
nies on selective (P-gal) plates vs. the number of coloniesJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/7
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on permissive (X-gal) plates times the dilution factor
(1,000 ×).
Statistical analysis
Variability in the mutant frequency data was examined
according to a binomial variance statistic as described
[9,10]. The binomial variance statistic is referenced to a
chi-square distribution with df equal to the number of
organs minus one. Significant excess variability is noted if
the statistic is larger than the upper 5% point from this ref-
erence distribution. If at any level the binomial variance
statistic fails to identify excess variability, the individual
observations are used to calculate a pooled mutant fre-
quency as a more precise estimate of the true mutant fre-
quency π. Comparisons between organs were performed
using a two-sided paired t-test.
Results
The average (± SD × 10-5) spontaneous mutant frequency
for liver, kidney, and spleen were 6.69 ± 0.60 (n = 4), 5.60
± 0.42 (n = 4), and 6.16 ± 1.06 (n = 4), respectively for
female mice and 6.37 ± 1.11 (n = 4), 4.59 ± 0.40 (n = 4),
and 5.98 ± 0.79 (n = 4), respectively for male mice. The
spontaneous mutant frequencies in kidney, liver and
spleen were not significantly different between female and
male mice. Moreover, the average spontaneous mutant
frequency in spleen was not significantly different from
the average spontaneous mutant frequency in liver and
only slightly, albeit not significantly, higher from the aver-
age spontaneous mutant frequency in kidney (Figure 1). It
should be noted, however, that despite similar spontane-
ous mutant frequencies the proportion of no-change and
size-change mutants may vary widely between organs. A
previous study on spontaneous mutant frequencies in
lacZ  plasmid-based transgenic mice indicated that the
proportion of size-change mutants in tissues with a rela-
tively high cell turnover (liver, lung and spleen) is signifi-
cantly higher as compared to tissues with a relatively low
cell turnover (brain and kidney) [11].
In order to understand the mechanism by which peroxi-
some proliferators attribute to rodent hepatocarcinogene-
sis the possible role of genetic toxicity should not be
dismissed if just one peroxisome proliferator is shown to
be unequivocally inactive as a genetic toxin. Based on
recent findings that WY-14,643 is mutagenic [7,12], pos-
sibly mediated through oxidative stress [8], this study
aimed to determine whether other peroxisome prolifera-
tors are mutagenic as well. To address this issue, lacZ plas-
mid-based transgenic mice were treated with WY-14,643,
DEHP, or clofibrate and mutant frequencies were meas-
ured in liver, the common target organ in rodents for
these three compounds. Mutant frequencies in kidney and
spleen were also measured after exposure to DEHP (both
organs) or WY-14,643 (kidney only).
The number of animals per group and the number of
CFUs per tissue determine the statistical power that can be
achieved at a given false positive rate. Since the number of
CFUs that can be analyzed in a single experiment on a sin-
gle plate can be as high as 2 × 106, it is not necessary to
consider the number of experiments per sample. A previ-
ous analysis of the lacZ mutant frequency for sources of
statistical variability showed that excess variability was
not evidenced from rescue-to-rescue (within-organ) [10].
In general, by comparing the data as two binomial pro-
portions using a one-sided test with significance level α =
0.05 and power 0.90, it has been estimated that in order
to detect an approximate 50% increase above an average
background mutant frequency of 5.5 to 7.0 × 10-5 using 4
animals per treatment group, approximately 1 × 106 CFUs
per group need to be analzyed.
The results shown in Figure 1 clearly indicate that the six-
dose exposure to DEHP or WY-14,643 over a two week
time period significantly increased the mutant frequency
in liver of both female and male mice by approximately
40%. In contrast, treatment with clofibrate did not lead to
an increased mutant frequency in liver of either female or
male mice. The mutant frequencies in kidney or spleen
were not significantly different between female and male
control mice and DEHP-exposed mice. Moreover, treat-
ment with WY-14,643 did not lead to a significant
increase in the mutant frequency of either female or male
kidney. The absence of a carcinogen-induced increase in
the mutant frequencies of kidney and spleen can not be
attributed to a lack of sensitivity of the lacZ plasmid-based
mice as outlined above and thus confirms the organ-spe-
cific mutagenic nature of DEHP and WY-14,643.
Discussion
Transgenic rodent gene mutation models provide the
means to determine gene mutations in the DNA from any
tissue in a relatively quick way. The lacZ plasmid-based
transgenic mouse mutation assay is somewhat unique
among other, commercially available, models (e.g., Muta-
Mouse™ and Big Blue™), by virtue of its ability to accu-
rately quantify both point mutations and large deletions
including those which originate in the lacZ plasmid con-
catamer and extend into the 3' flanking genomic region
[13]. It should be noted that to date there is no single,
agreed-upon protocol for conducting mutagenicity assays
with transgenic rodents although several aspects have
been agreed upon by the Transgenic Mutation Assays
Workgroup of the International Workshop on Genotoxic-
ity Procedures [14,15]. In this study, the duration of treat-
ment (two weeks), the number of treatments (six), as well
as the manifestation time of 21 days (i.e., the time
between the last treatment and the time of sampling) were
chosen based on the rationale that multiple treatments
generally produce a larger response than single treatmentsJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/7
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Transgenic lacZ mutant frequencies in organs exposed to peroxisome proliferators Figure 1
Transgenic lacZ mutant frequencies in organs exposed to peroxisome proliferators. Female (solid bars) and male (hatched 
bars) mice were treated with six doses of 2,333 mg DEHP, 200 mg WY-14,643, or 90 mg clofibrate per kg of bodyweight, 
respectively, over a two-week period. Twenty-one days after the last treatment, animals were sacrificed and organs were fro-
zen at -80°C until used for DNA isolation. The binomial variance statistic is referenced to a λ2 distribution with df equal to the 
number of organs minus one. Comparisons between organs were performed using a two-sided paired t-test. Mutant frequen-
cies in liver exposed to the peroxisome proliferators DEHP or WY-14,643 were significantly different from mutant frequencies 
in unexposed livers at P < 0.01 (*) or P < 0.025 (#). All other comparisons were not significant.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/7
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[15] and sampling time should not exceed 2–4 weeks. The
latter requirement is based on recent findings that the
mutant frequency may actually decline, even in tissues
characterized by a long turnover time of the cell popula-
tion [11,16]. The observation that carcinogen-induced
mutant frequencies do not necessarily increase and then
remain constant over time indicates that cell proliferation
is not the only factor determining whether, and to what
extent, mutations are evident in a particular tissue as was
previously surmised (Bielas and Heddle, 2000). Although
in the present study there was no statistically significant
difference in the average spontaneous mutant frequencies
of liver, kidney, and spleen, it has been demonstrated pre-
viously, using a greater number of animals, that the aver-
age spontaneous mutant frequency in liver is significantly
higher as compared to the average spontaneous mutant
frequencies in kidney and spleen [10].
DEHP was recently downgraded by a working group of
International Agency for Research on Cancer (IARC) from
"a possible or reasonably anticipated human carcinogen"
to "not classifiable as to its carcinogenicity to humans"
(group 3) based on the assertion that DEHP produces
liver tumors in rats and mice by a mechanism involving
peroxisome proliferation, which was judged to be not rel-
evant to humans [17]. Similarly, clofibrate has been clas-
sified as not classifiable as to its carcinogenicity in
humans [18] while Wyeth 14,643 has not been evaluated
yet. Both DEHP and Wyeth 14,643 are typically consid-
ered rodent carcinogens that are putative human non-car-
cinogens based on their mechanism of action while
clofibrate is considered a rodent carcinogen that is a puta-
tive human non-carcinogen based on epidemiological
data.
Oral repeat-dose studies in rats and mice have consist-
ently shown that the primary target organ of these chemi-
cals is the liver [19]. However, in contrast to DEHP and
WY-14,643, clofibrate produced hepatocellular carcino-
mas in rats only while no increase in the incidence of
tumors was reported in mice [19]. If peroxisome prolifer-
ation alone is predictive of liver cancer outcome, then
similar levels of peroxisome proliferation should lead to
similar incidences of liver tumors in experimental ani-
mals. However, this is not always the case. For example, at
doses of DEHP and WY-14,643 that produce similar levels
of peroxisome proliferation in rat liver, WY-14,643 pro-
duced an earlier and much greater liver tumor response
than did DEHP [20]. Additionally, clofibrate induces per-
oxisome proliferation in both rats and mice [21] but only
produced hepatocellular carcinomas in rats [19]. Thus,
peroxisome proliferation alone does not provide an ade-
quate mechanistic explanation for the different, species-
specific, carcinogenic potencies of DEHP, WY-14,643 and
clofibrate in rodent liver. Indeed, based on the relation-
ship between the observed mutagenic potential of DEHP,
WY-14,643 and clofibrate in female and male lacZ plas-
mid-based transgenic mice and their reported carcino-
genic potencies in rodent liver, the classification of
peroxisome proliferators as non-genotoxic may need to be
reconsidered.
Several studies from a government/industry/academic
partnership, coordinated by the International Life Sci-
ences Institute (ILSI), have recently evaluated several alter-
native models for their sensitivity in identifying
carcinogens, including clofibrate, WY-14,643 and DEHP.
Among these models were the TgAC transgenic mouse
model (employing both dermal and oral administration)
[22], the Tg-rasH2 transgenic model [23], the hetero-
zygous p53 gene knockout model [24], the homozygous
XPA and the homozygous XPA-heterozygous p53 gene
knockout models [25], and the neonatal mouse model
[26]. The chemicals were also evaluated in the in vitro SHE
assay. The data presented in Table 1 indicates that each of
these peroxisome proliferators produced positive or
equivocal results in 1 or more of the aforementioned
models, and each of the models, except for the neonatal
mouse model, gave positive or equivocal results with 1 or
more of these three chemicals. The data presented in Fig-
ure 1 and Table 1 indicates that, based on the observed
mutant frequencies, the lacZ transgenic mouse mutation
assay correctly predicted the organ-specific carcinogenic
potential of these three peroxisome proliferators in mice.
In contrast, the other eight alternative models were unable
to unambiguously predict the carcinogenic action of clof-
ibrate, WY-14,643 and DEHP and in most instances did
not yield any potential information on the organ-specific
Table 1: Mutagenicity of peroxisome proliferators in various models
Chemical Ratsa Micea Genotoxb lacZ P53+/- RasH2 TgAC-dermal TgAC-oral XPA-/- XPA/p53 Neonatal SHE
Clofibrate + - - -(IP)c -(G) +/Eq.(G) + In. -
WY-14,643 + + - +(IP) -(diet) - Eq.(diet) + +
DEHP + + - +(IP) Eq. +(diet) - -(diet) - - -
aResults from standard long-term (18–24 months) bioassay. bPrimarily related to results in the Ames assay as a reasonable indicator of reactivity of 
the chemical or a metabolite with DNA. cIP = intraperitoneal; G = gavage; In = Inadequate; Eq = equivocal.Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/7
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action of these peroxisome proliferators (Table 1). The
variable results obtained with peroxisome proliferators
may be related to the mechanism(s) by which they are
producing tumors. These chemicals act by producing a
strongly oxidative damaging milieu and, as such, may
exert a genotoxic effect which, in combination with a con-
current increase in hepatocellular proliferation, would
ultimately lead to hepatocellular carcinogenesis.
Several lines of evidence support the notion that peroxi-
some proliferators may indeed be exerting a genotoxic
effect, albeit not in all exposed tissues or organs. First, WY-
14-643, a more potent carcinogen than DEHP, was more
active in inducing chromosome aberrations in a study of
morphologic transformation in Syrian hamster embryo
(SHE) cells [27]. Second, several peroxisome proliferators,
including DEHP, WY-14,643, clofibrate and simfibrate
were shown to produce DNA damage in vitro as well as in
vivo [12,28,29]. Third, male B6C3F1 Big Blue transgenic
mice which were fed a diet containing WY-14,643 dis-
played a significant increase in their liver mutant fre-
quency, as compared to untreated control mice [12].
Conclusions
The organ-specific mutagenicity of two peroxisome prolif-
erators, DEHP and WY-14,643, has been unambiguously
established using the lacZ  plasmid-based transgenic
mouse mutation model. Moreover, exposure to clofibrate
did not result in an elevated mutant frequency in mouse
liver, consistent with the historical observation that this
compound does not increase the incidence of tumors in
mice. These results suggest that peroxisome proliferation
may not be the only necessary factor in the carcinogenicity
of DEHP and WY-14,643, and perhaps other peroxisome
proliferators as well, thereby contending the prevailing
opinion that peroxisome proliferators do not pose a carci-
nogenic risk to humans because of species differences in
peroxisome proliferation. The elucidation of the mecha-
nistic action(s) of peroxisome proliferators including oxi-
dative damage, perturbation of growth control
(enhancement of cell proliferation and suppression of
apoptosis) as well as mutagenicity and carcinogenicity
should greatly aid our ability to determine whether these
agents do indeed pose a cancer risk to humans.
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